Evidence map›Paper›PMID 18406591›Full record

ReviewCurrent opinion in immunology2008

Emerging concepts in CD8(+) T regulatory cells.

Jerry Y Niederkorn

Abstract readReview
In one paragraph

Review in Current opinion in immunology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed.

  1. Interferon regulatory factors orchestrate CD8International journal of molecular medicine · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Frontiers in immunology · 2017
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. A Bone Anabolic Effect of RANKL in a Murine Model of Osteoporosis Mediated Through FoxP3+ CD8 T Cells.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2015
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Regulatory T cells in chronic lymphocytic leukemia: implication for immunotherapeutic interventions.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2013
    Review
  19. The Interplay between the bone and the immune system.Clinical & developmental immunology · 2013
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Jerry Y NiederkornDepartment of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. jerry.niederkorn@utsouthwestern.edu

Funding

TRANSPLANT AND TUMOR REJECTION PROCESSES WITHIN THE EYER01EY005631 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI NIEDERKORN, JERRY · 1985 to 2015
$5.8M
THE IMMUNOBIOLOGY OF CORNEAL ALLOGRAFTSR01EY007641 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI NIEDERKORN, JERRY · 1988 to 2016
$5.6M
INFRASTRUCTIRE DEVELOPMENT GRANT FOR CORNEA RESEARCHR24EY016664 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI PETROLL, W MATTHEW · 2005 to 2009
$1.2M
NEI NIH HHS EY005631NEI NIH HHS EY007641NEI NIH HHS EY016664NEI NIH HHS R01 EY005631NEI NIH HHS R01 EY007641NEI NIH HHS R24 EY016664
6 · The paper itself

Abstract

CD8(+) T regulatory cells (T regs) are elicited by unique antigen presenting cells during viral infections, by manipulation of co-stimulatory molecules, or in the development of tumors. CD8(+) T regs display antigen-specificity, which is most exquisitely manifested by the HLA-E-restricted cytolytic CD8(+) T regs in MS. There is evidence that some CD8(+) T regs also express organ specificity. In many cases, IFN-gamma is required for either the induction or expression of CD8(+) T regs. CD8(+) T regs can produce suppression directly by killing immune cells or indirectly by co-opting other cells to elaborate end-stage suppressive molecules such as TGF-beta, IL-10, and indoleamine dioxygenase (IDO).

Indexed as

AnimalsAntigensCD8-Positive T-LymphocytesLymphocyte ActivationMultiple SclerosisNeoplasmsT-Lymphocytes, RegulatoryT-Lymphocyte SubsetsAntigens

Identifiers

PMID18406591
PMCPMC2525788

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.